We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.62B
1-Year Est. Return 138.67%
This Fund
S&P 500
This Quarter Est. Return
+32.4%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$903M
AUM Growth
+$291M
Cap. Flow
+$109M
Cap. Flow %
12.02%
Top 10 Hldgs %
78.43%
Holding
34
New
4
Increased
10
Reduced
5
Closed
10

Top Buys

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$31.7M
2
MOR
MorphoSys AG American Depositary Shares
MOR
+$31.1M
3
IMGN
Immunogen Inc
IMGN
+$28.3M
4
COGT icon
Cogent Biosciences
COGT
+$27.9M
5
DVAX
Dynavax Technologies
DVAX
+$14.1M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$30.2M
2
PCVX icon
Vaxcyte
PCVX
+$15.6M
3
TSHA icon
Taysha Gene Therapies
TSHA
+$10.4M
4
CLDX icon
Celldex Therapeutics
CLDX
+$5.71M
5
OLMA icon
Olema Pharmaceuticals
OLMA
+$2.9M

Sector Composition

Rank Sector Weight
1 Healthcare 97.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GOSS icon
26
Gossamer Bio
GOSS
$66.5M
– –
-250,000
Closed -$208K
GYRE icon
27
Gyre Therapeutics
GYRE
$662M
– –
-6,004
Closed -$43.4K
IMVT icon
28
PUT
Immunovant
IMVT
$8.09B
– –
-100,000
Closed -$3.84M
NGNE icon
29
Neurogene
NGNE
$696M
– –
-6,009
Closed -$94.9K
OLMA icon
30
Olema Pharmaceuticals
OLMA
$1.02B
– –
-235,176
Closed -$2.9M
PBYI icon
31
Puma Biotechnology
PBYI
$406M
– –
-473,975
Closed -$1.25M
SNDX icon
32
CALL
Syndax Pharmaceuticals
SNDX
$1.84B
– –
-400,000
Closed -$5.81M
TSHA icon
33
Taysha Gene Therapies
TSHA
$1.59B
– –
-3,281,313
Closed -$10.4M
TVTX icon
34
CALL
Travere Therapeutics
TVTX
$5.33B
– –
-15,100
Closed -$135K
1
2

Similar funds

IPW
Invictus Private Wealth Denver, Colorado $1.62B AUM 22.63% 1-Year Est. Return
WIC
Woodmont Investment Counsel Nashville, Tennessee $1.62B AUM 18.92% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
TLFA
True Link Financial Advisors San Francisco, California $1.62B AUM 8.33% 1-Year Est. Return
KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
PRA
Pine Ridge Advisers New York $1.62B AUM 16.97% 1-Year Est. Return
BW
Browning West Los Angeles, California $1.62B AUM 22.28% 1-Year Est. Return
CC
Covalis Capital London, United Kingdom $1.63B AUM 27.84% 1-Year Est. Return

Kynam Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Kynam Capital Management held 34 positions worth $903M, up 48% from $611M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Kynam Capital Management deployed $109M of net new capital in Q4 2023, opening 4 new positions and adding to 10 existing holdings. Its largest new stake was MorphoSys AG American Depositary Shares: 4,234,685 shares worth $41.9M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier.

On the sell side, the largest reduction was Natera, an estimated $30.2M trimmed.

  • Kynam Capital Management's largest Q4 2023 buy was MorphoSys AG American Depositary Shares: 4,234,685 shares worth $41.9M.
  • Kynam Capital Management added most to Syndax Pharmaceuticals in Q4 2023, an estimated $31.7M increase.
  • Kynam Capital Management's biggest Q4 2023 reduction was Natera, cutting an estimated $30.2M.
  • Kynam Capital Management fully exited Taysha Gene Therapies in Q4 2023, selling an estimated $10.4M.
  • Kynam Capital Management's ten largest holdings make up 78% of its $903M portfolio in Q4 2023.
  • Kynam Capital Management opened 4 new positions and closed 10 in Q4 2023.
  • Kynam Capital Management's portfolio value rose 48% quarter-over-quarter to $903M.

Based on Kynam Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.